Pharmacologic treatments for covid-19 patients
C1 Esterase/Kallikrein Inhibitor vs Standard care
This comparison will not be updated. Last search date 28 Feb, 2022.
Hospitalized patients
Forest plots
(last update: 2020-11-20)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=55
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| RBR-5s2mqg Mansour E, medRxiv, 2020 Full text Commentary |
Public/non profit |
Icatibant C1 Esterase/Kallikrein Inhibitor Icatibant |
Standard care Standard care C1 Esterase/Kallikrein Inhibitor |
RCT | Patients with COVID-19 (severe) admitted to a single center in Brazil | N=30 |
Some concerns Details |
|